| Authors: |
Zyumbileva P; Université Paris-Saclay, Gustave Roussy, Inserm, CESP, F-94805, Villejuif, France; Université Paris-Saclay, Gustave Roussy, Inserm, CESP, IHU PRISM National PRecISion Medicine Center in Oncology, F-94800, Villejuif, France; Charité - Universitätsmedizin Berlin, Berlin, Germany. Electronic address: petya.zyumbileva@gustaveroussy.fr., Spanic T; Europa Donna-The European Breast Cancer Coalition, Milan, Italy; Europa Donna Slovenia, Ljubljana, Slovenia., Gillanders E; Université Paris-Saclay, Gustave Roussy, Inserm, CESP, F-94805, Villejuif, France., Martin E; Université Paris-Saclay, Gustave Roussy, Inserm, CESP, F-94805, Villejuif, France., Zambon M; Europa Donna-The European Breast Cancer Coalition, Milan, Italy., Connolly M; European Patients' Academy on Therapeutic Innovation (EUPATI), Amsterdam, the Netherlands., Dutarte M; European Patients' Academy on Therapeutic Innovation (EUPATI), Amsterdam, the Netherlands., Tricanico E; European Patients' Academy on Therapeutic Innovation (EUPATI), Amsterdam, the Netherlands., Caballero C; Breast International Group, Brussels, Belgium., El-Abed S; Breast International Group, Brussels, Belgium., Dunn J; Warwick Medical School, University of Warwick, Coventry, UK., Merckaert I; Jules-Bordet-Institut, Brussels, Belgium., Macpherson IR; School of Cancer Sciences, University of Glasgow, UK., Vanhecke A; UNICANCER, Paris, France., Vaz-Luis I; Université Paris-Saclay, Gustave Roussy, Inserm, CESP, F-94805, Villejuif, France; Université Paris-Saclay, Gustave Roussy, Inserm, CESP, IHU PRISM National PRecISion Medicine Center in Oncology, F-94800, Villejuif, France; Interdisciplinary Department for the Organization of Patient Pathways (DIOPP), Gustave Roussy, Villejuif, France., Franzoi MA; Université Paris-Saclay, Gustave Roussy, Inserm, CESP, F-94805, Villejuif, France; Université Paris-Saclay, Gustave Roussy, Inserm, CESP, IHU PRISM National PRecISion Medicine Center in Oncology, F-94800, Villejuif, France. |
